Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular ...

Read Our Latest Research Report on Novo Nordisk A/S Novo Nordisk A/S Stock Performance NYSE:NVO opened at $86.41 on Friday. The firm has a market capitalization of $387.77 billion, a PE ratio of ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate nipocalimab for the treatment of generalized myasthenia gravis (gMG). The ...

Novo Nordisk announced that it is expanding its previous collaboration with Valo Health to discover and develop novel treatments for cardiometabolic diseases. The companies had originally signed ...